Director's Dealing • Aug 8, 2023
Director's Dealing
Open in ViewerOpens in native device viewer
Washington, D.C. 20549
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
Check this box if no longer subject to Section 16. Form 4 or
Instruction 1(b).
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| Elstein | 1. Name and Address of Reporting Person Amir |
2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Ltd. [TEVA] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _ 10% Owner X Director _ Officer (give title below)____ Other (specify below) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Last) 124 Dvora HaNevi'a St., |
(First) C/O Teva Pharmaceutical Industries Ltd. |
(Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 08/04/2023 |
|||||||
| (Street) Tel Aviv |
L3 | 6944020 | 4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person |
||||||
| (City) | (State) | (Zip) | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |
| 1.Title of Security (Instr. 3) |
2. Transaction Date (Month/Day/Year) |
2A. Deemed Execution Date, if any (Month/Day/Year) |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) |
6. Ownership Form: |
7. Nature of Indirect Beneficial |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | Amount | (A) or (D) |
Price | (Instr. 3 and 4) | Direct (D) or Indirect (I) (Instr. 4) |
Ownership (Instr. 4) |
|||
| (1) Ordinary Shares |
08/04/2023 | M | 15,810 | A | (2) | 2,073,223 | D |
| 1. Title of Derivative Security (Instr. 3) |
2. 3. Transaction Conversion Date or Exercise (Month/Day/Year) Price of Derivative Security |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
(Instr. 4) | (Instr. 4) | ||||||
| Restricted Share Units |
(2) | 08/04/2023 | M | 15,810 | (3) | (3) | Ordinary Shares (1) |
15,810 | \$ 0 |
0 | D |
(1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
/s/ Dov Bergwerk as attorney-in-fact for Amir Elstein 08/07/2023
**Signature of Reporting Person Date
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.